Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells: Physiological responses

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Oliver III, Robert ^a   Friday, Ellen ^a,b   Turturro, Francesco ^a,b   Lacy, Ashley ^a   Welbourne, Tomas ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center   (United States)

Author keywords

Ammoniagenesis; DNA synthesis; Intracellular pH; Non volatile acid production; P ERK; Peroxisome proliferator activated receptor independent; Sodium hydrogen exchanger

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACID; DNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM PROTON EXCHANGE PROTEIN; TROGLITAZONE;

ACIDOSIS; AMMONIA FORMATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PH; CELL STRAIN; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 18744409101     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00205.2004     Document Type: Article

References (50)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, and Saltei AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995.
2. Alpern RJ. Trade-offs in the adaptation to acidosis. Kidney Int 47: 1205-1215, 1995.
3. + exchanger (NHE1 isoform) in response to growth factors. J Biol Chem 272: 271-279, 1997.
4. Bischof G, Cosentini E, Hamilton G, Riegler M, Zacherl J, Teleky B, Feil W, Schiessel R, Machen T, and Wenzl E. Effects of extracellular pH on intracellular pH regulation and growth in the human colon carcinoma cell line. Biochim Biophys Acta 1282: 131-139, 1996.
5. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, and Leff T. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 49: 539-547, 2000.
6. Coates G, Nissim I, Battarbee H, and Welbourne T. Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells. Am J Physiol Endocrinol Metab 283: E729-E737, 2002.
7. Curthoys NP and Gstraunthaler G. Mechanism of increased renal gene expression during metabolic acidosis. Am J Physiol Renal Physiol 281: F381-F390, 2001.
8. Davies SP, Reddy H, Caivano M, and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
9. De Dios ST, Hannan KM, Dilley RJ, Hill MA, and Little PJ. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complications 15: 120-127, 2001.
10. Ecelbarger CA and Welbourne T. Rosiglitazone increases renal sodium/hydrogen exchanger 3 protein and ammonium excretion in young rats. FASEB J 16: 1169A, 2002.
11. Ghosh S, Gehr T, Ghosh S, Fakhry I, Sica D, Lyall V, and Schoolwerth A. PPARγ ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 64: 52-62, 2003.
12. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, and Sachinidis A. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn Schmiedebergs Arch Pharmacol 363: 215-221, 2001.
13. + cells. Am J Physiol Cell Physiol 270: C825-C831, 1996.
14. Gstraunthaler G and Handler JS. Isolation, growth, and characterization of a gluconeogenic strain of renal cells. Am J Physiol Cell Physiol 252: C232-C238, 1987.
15. + cells. Am J Physiol Renal Physiol 278: F227-F237, 2000.
16. 2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 314: 1093-1099, 2004.
17. + exchanger NHE1 by sustained intracellular acidosis: evidence for a novel mechanism mediated by the ERK pathway. J Biol Chem 278: 31676-31684, 2003.
18. 1 renal epithelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 263: F83-F88, 1992.
19. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, and Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49: 1022-1032, 2000.
20. Keshamouni V, Reddy R, Arenberg D, Joel B, Thannickal V, Kalemkerian G, and Standiford T. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 100-108, 2004.
21. Lennon AM, Ramauge M, Dessouroux A, and Pierre M. MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Δ12-4-prostaglandin J2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygen species. J Biol Chem 277: 29681-29685, 2002.
22. Lotspeich WD. Renal hypertrophy in metabolic acidosis and its relation to ammonia excretion. Am J Physiol 208: 1135-1142, 1965.
23. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient vs. sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
24. McCarthy KJ, Routh RE, Shaw W, Welbourne TC, and Johnson JH. Troglitazone halts diabetic glomerulosclerosis. Kidney Int 58: 2341-2350, 2000.
25. Montcourrier P, Silver I, Farnoud R, Bird I, and Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 15: 382-392, 1997.
26. + cells to metabolic acidosis. Am J Physiol Cell Physiol 270: C920-C925, 1996.
27. Mukhin YV, Garnovskaya MN, Ullian ME, and Raymond JR. ERK is regulated by sodium-proton exchanger in rat aortic vascular smooth muscle cells. J Biol Chem 279: 1845-1852, 2004.
28. + exchanger isoforms (NHE1 and NHE3) in polarized epithelial cell lines. J Cell Sci 109: 929-939, 1996.
29. mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90: 8319-8323, 1993.
30. Park H, Lyns J, Ohtsuba T, and Song C. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer 80: 1892-1897, 1999.
31. Pirkebner D, Fuetsch M, Wittmann W, Weiss H, Haller T, Schramek H, Margreiter R, and Amberger A. Reduction of intracellular pH inhibits constitutive expression of cyclooxygenase-2 in human colon cancer cells. J Cell Physiol 198: 295-301, 2003.
32. Putney LK and Barber DL. Na-H exchange increase in intracellular pH times G2/M entry and transition. J Biol Chem 278: 44645-44649, 2003.
33. Roovers K and Assoian R. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22: 818-826, 2000.
34. Routh R, McCarthy K, and Welbourne T. Troglitazone inhibits glutamine metabolism in rat mesangial cells. Am J Physiol Endocrinol Metab 282: E231-E238, 2002.
35. Rumi MA, Ishihara S, Kadowaki Y, Ortega-Cava C, Kazumori H, Kawashima K, Yoshino N, Yuki T, Ishimura N, and Kinoshita Y. Peroxisome proliferator- activated receptor γ-dependent and -independent growth inhibition of gastrointestinal tumor cells. Genes Cells 9: 1113-1123, 2004.
36. Seargent J, Yates E, and Gill J. GW9662, a potent antagonist of PPARγ inhibits growth of breast tumor cells and promotes the anticancer effects of PPARγ agonist rosiglitzone, independently of PPAR activation. Br J Pharmacol 143: 933-937, 2004.
37. Simpson D. Citrate excretion: a window on renal metabolism. Am J Physiol Renal Fluid Electrolyte Physiol 244: F223-F234, 1983.
38. Souza RF, Shewmake K, Pearson S, Sarosi GA Jr, Feagins LA, Ramirez RD, Terada LS, and Spechler SJ. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 287: G743-G748, 2004.
39. Takeda K, Ichiki T, Tokunou T, Lino N, and Takeshita A. 15-Deoxy-Δ12, 14 prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 276: 48950-48955, 2001.
40. Tsuganezawa H, Sato S, Yamaji Y, Preisig PA, Moe OW, and Alpern RJ. Role of c-SRC and ERK in acid-induced activation of NHE3. Kidney Int 62: 41-50, 2002.
41. Turturro F, Friday E, Fowler R, Surie D, and Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroisome proliferator-activated receptor γ-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 10: 7022-7030, 2004.
42. Wang W, Wise SC, Leff T, and Su TZ. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ. Diabetes 48: 254-260, 1999.
43. + exchange. J Biol Chem 274: 7841-7847, 1999.
44. - absorption by nerve growth factor in MTAL. Am J Physiol Renal Physiol 282: F1056-F1063, 2002.
45. + acid-base metabolism. Am J Physiol Renal Physiol 286: F100-F110, 2004.
46. Welbourne T and Nissim I. Acidosis and amino acid metabolism. In: Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition, 2nd edition, edited by Cynober L. Boca Raton, FL: CRC, 2004, p. 375-388.
47. Welbourne T, Su G, Coates G, Routh R, McCarthy K, and Battarbee H. Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells. Am J Physiol Regul Integr Comp Physiol 282: R1600-R1607, 2002.
48. Wilkins R and Hall A. Control of matrix synthesis in isolated bovine chondrocytes by extracellular and intracelluar pH. J Cell Physiol 164: 474-481 1995.
49. + exchanger. Am J Physiol Renal Physiol 284: F829-F839, 2003.
50. Yang X, Amemiya M, Peng Y, Moe O, Preisig P, and Alpern R. Acid incubation causes exocytic insertion of NHE3 in OKP cells. Am J Physiol Cell Physiol 279: C410-C419, 2000.